|By PR Newswire||
|August 25, 2014 11:43 AM EDT||
MARLBOROUGH, Mass., Aug. 25, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released additional research and comments on Ligand Pharmaceuticals (NASDAQ: LGND) amidst the company's unusual and complex debt arrangement under which the firm has assumed $245 million in debt principally so that large institutional shareholders can offload shares of the troubled company in private transactions at undisclosed prices. In what is likely the first in a series of large institutional share sales of Ligand, the company's largest shareholder, BVF, Inc., revealed to the U.S. Securities and Exchange Commission (SEC) this week that it has sold 484,524 shares of the company's stock.
"Ligand Pharmaceuticals is an insolvent company facing severe competitive threats to its key royalty programs that has now absorbed an extraordinary amount of costly debt apparently to allow their largest shareholders to liquidate their holdings as 'going concern risk' at the company grows," Lemelson Capital Management Chief Investment Officer Emmanuel Lemelson said today. "This transaction reaffirms our prior research thesis that Ligand has justifiably lost favor with its largest investors and has dramatically increased the likelihood of the company eventually being forced to seek protection from creditors," he added.
The report on Ligand can be found here.
Lemelson Capital Management first announced its short position in Ligand Pharmaceuticals on June 16, 2014. The stock has undergone a significant 26 percent correction since. "We reiterate our position that the intrinsic value for Ligand is zero and see these large institutional sales as an indication that our concerns are increasingly broadly held," Lemelson said.
Disclosure: Lemelson Capital is currently short shares of LGND for its clients.
About Lemelson Capital Management:
Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds. For more information, see: http://www.lemelsoncapital.com.
Chief Investment Officer
Lemelson Capital Management, LLC
SOURCE Lemelson Capital Management, LLC
Aug. 24, 2016 09:15 PM EDT Reads: 1,656
Aug. 24, 2016 04:45 PM EDT Reads: 1,295
Aug. 24, 2016 04:35 PM EDT Reads: 279
Aug. 24, 2016 04:15 PM EDT Reads: 331
Aug. 24, 2016 04:15 PM EDT Reads: 444
Aug. 24, 2016 04:15 PM EDT Reads: 2,551
Aug. 24, 2016 04:10 PM EDT Reads: 271
Aug. 24, 2016 03:15 PM EDT Reads: 390
Aug. 24, 2016 02:15 PM EDT Reads: 1,434
Aug. 24, 2016 02:00 PM EDT Reads: 1,830
Aug. 24, 2016 02:00 PM EDT Reads: 467
Aug. 24, 2016 12:15 PM EDT Reads: 1,795
Aug. 24, 2016 12:00 PM EDT Reads: 3,846
Aug. 24, 2016 11:45 AM EDT Reads: 1,435
Aug. 24, 2016 11:45 AM EDT Reads: 3,354